CINCINNATI and HUNTSVILLE, Alabama, May 15, 2024 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug delivery platform and Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its POZ Platform™ to develop and improve efficacy and safety across multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs), today announced a partnership to develop and commercialize SER-252 (POZ-apomorphine) in combination with enFuse for the treatment of Parkinson’s disease..

辛辛那提和阿拉巴马州亨茨维尔，2024年5月15日（环球通讯社）--Enable Injections，Inc.（“Enable”），一家开发和制造enFuse®可穿戴药物递送平台和Serina Therapeutics（“Serina”）的医疗创新公司（NYSE American:SER），一家临床阶段生物技术公司，推进其POZ platform™开发和提高多种模式（包括小分子，基于RNA的治疗和基于抗体的药物偶联物（ADC））的疗效和安全性，今天宣布建立合作伙伴关系，将SER-252（POZ-apomorphine）与enFuse联合用于治疗帕金森病。。

SER-252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson’s disease. Preclinical studies support the potential of SER-252 to provide CDS without skin reactions.

SER-252是一种使用Serina的POZ平台开发的研究性阿扑吗啡疗法，旨在提供连续的多巴胺能刺激（CDS）。CDS已被证明可以降低帕金森病中左旋多巴相关运动并发症（运动障碍）的严重程度。临床前研究支持SER-252在没有皮肤反应的情况下提供CD的潜力。

Serina plans to advance SER-252 to clinical testing in 2025..

丝氨酸计划在2025年将SER-252推进临床测试。。

enFuse is an innovative, wearable drug delivery platform designed to deliver large volumes of medications subcutaneously, in which patients receive their needed treatment in a simple injection under the skin, instead of intravenously. enFuse is designed to overcome both IV infusion and other subcutaneous administration method shortcomings through fast, simple, and convenient delivery, benefiting patients, providers, as well as payers, with the ability for patient self-administration..

enFuse是一种创新的可穿戴药物输送平台，旨在皮下输送大量药物，患者只需在皮肤下注射即可接受所需治疗，而不是静脉注射。enFuse旨在通过快速，简单和方便的递送来克服静脉输注和其他皮下给药方法的缺点，使患者，提供者以及付款人受益，并具有患者自我给药的能力。。

“Current apomorphine treatments require daily and time-consuming infusions through an electronic pump that not only burdens patients and providers, but can cause significant skin reactions,” said Randall Moreadith, M.D., Ph.D., Chief Development Officer of Serina Therapeutics. “With enFuse, patients can self-administer SER-252 in the convenience of their home with wearable technology and with a rapid treatment time.

Serina Therapeutics首席开发官Randall Moreadith医学博士说：“目前的阿扑吗啡治疗需要每天通过电子泵进行耗时的输注，这不仅会给患者和提供者带来负担，还会引起严重的皮肤反应。”。“使用enFuse，患者可以通过可穿戴技术在家中方便地自我管理SER-252，并且治疗时间很快。

If effective, a SER-252 and enFuse combination provides the potential for patients to remain in a continuous ‘ON’ state and avoid dyskinesia.”.

如果有效，SER-252和enFuse的组合可以使患者保持持续的“开启”状态并避免运动障碍。”。

“The partnership with Serina Therapeutics continues to validate the applicability of enFuse across various therapeutic areas, even in the field of Parkinson’s, where multiple routes of treatment administration already exist, including subcutaneous methods. The technology and benefits of enFuse have the potential to significantly reduce many of the burdens associated with the current standard of care for Parkinson’s,” said Mike Hooven, Chairman and CEO of Enable Injections.

Enable注射剂董事长兼首席执行官迈克·霍文（MikeHooven）表示：“与丝氨酸治疗公司（Serina Therapeutics）的合作伙伴关系继续验证enFuse在各个治疗领域的适用性，即使在帕金森氏症领域也是如此，因为帕金森氏症已经存在多种治疗途径，包括皮下注射方法。enFuse的技术和益处有可能显着减轻与帕金森氏症当前护理标准相关的许多负担。”。

“We greatly look forward to bringing those living with, and treating, Parkinson’s disease an improved treatment experience that is more convenient, less time-consuming, and less disruptive to their lives with SER-252 in combination with enFuse.”.

“我们非常期待SER-252与enFuse联合使用，为帕金森病患者和治疗者带来更好的治疗体验，更加方便，耗时更少，对他们的生活破坏更小。”。

Enable is currently working with a number of pharmaceutical partners to conduct clinical trials and plan for joint commercial launch of their therapies in combination with the enFuse technology. Enable continues to selectively add to its list of pharmaceutical partners, with indications and patient populations who will benefit from the enFuse system.

Enable目前正在与许多制药合作伙伴合作进行临床试验，并计划结合enFuse技术联合商业推出其疗法。Enable继续有选择地将适应症和患者人群添加到其药物合作伙伴名单中，他们将从enFuse系统中受益。

The first enFuse combination product received U.S. Food and Drug Administration approval in 2023..

2023年，第一个enFuse组合产品获得了美国食品和药物管理局的批准。。

“In addition to advancing our pipeline of drug candidates, Serina is focused on partnering with pharmaceutical companies on its POZ Platform™ to improve the integrated safety and efficacy profile of small molecules, RNA-based therapeutics and ADCs. Serina’s collaboration with Enable is the first of many potential partnerships,” said Dr.

“除了推进我们的候选药物渠道之外，Serina还专注于与制药公司在其POZ Platform™上合作，以改善小分子，基于RNA的疗法和ADC的综合安全性和有效性。Serina与Enable的合作是许多潜在合作伙伴中的第一个，”Dr。

Simba Gill, Executive Chairman of Serina Therapeutics..

丝氨酸治疗学执行主席辛巴·吉尔。。

Under the terms of the agreement, Serina will obtain a worldwide, exclusive license to the enFuse platform for an upfront and future milestone payments. Enable will also be entitled to product sales and single digit royalties.

根据协议条款，Serina将获得enFuse平台的全球独家许可，用于预付款和未来里程碑付款。Enable还将有权获得产品销售和个位数的版税。

About Enable Injections

关于启用注入

Cincinnati-based Enable Injections is a global healthcare innovation company committed to improving the patient treatment experience through the development and manufacturing of enFuse®. enFuse is an innovative wearable drug delivery platform that is designed to deliver large volumes of pharmaceutical and biologic therapeutics via subcutaneous administration, with the aim of improving convenience, supporting superior outcomes, and advancing healthcare system economics.

总部位于辛辛那提的Enable Injections是一家全球医疗创新公司，致力于通过开发和制造enFuse®来改善患者的治疗体验。enFuse是一种创新的可穿戴药物递送平台，旨在通过皮下给药提供大量药物和生物治疗剂，旨在提高便利性，支持优异的结果，并推进医疗保健系统的经济性。

For more information about the Company’s approved enFuse combination production, visit https://enableinjections.com/our-products..

有关公司批准的enFuse组合生产的更多信息，请访问https://enableinjections.com/our-products..

About Serina Therapeutics

关于丝氨酸疗法

Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases, pain, and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).

Serina是一家临床阶段的生物技术公司，开发了一系列全资候选药物，用于治疗神经系统疾病，疼痛和其他适应症。Serina的POZ PlatformTM提供了改善多种方式（包括小分子，基于RNA的治疗剂和基于抗体的药物缀合物（ADC））的综合功效和安全性的潜力。

Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology..

Serina的总部位于阿拉巴马州亨茨维尔的HudsonAlpha生物技术研究所。。